Literature DB >> 1803865

Management of tumours involving the cavernous sinus.

L N Sekhar1, S Pomeranz, C N Sen.   

Abstract

The operative experience with 137 tumours of the cavernous sinus at the University of Pittsburgh during the past 7 years is reported. The importance of the normal and tumour-infiltrated cavernous sinus anatomy and imaging is delineated. 63% of the tumours are benign, primarily meningiomas, for which an anatomical grading system is presented. The various operative approaches to the cavernous sinus are described. 88% of the meningiomas were totally resected. There was a 1.5% operative mortality and 1.5% severe morbidity rate. Initial ipsilateral opthalmoplegia progressively improved in the majority of patients. For all patients with at least 6 months of follow up of benign tumours, the intracavernous tumour recurrence rate was 3% and total recurrence rate was 6%.

Entities:  

Mesh:

Year:  1991        PMID: 1803865     DOI: 10.1007/978-3-7091-9183-5_18

Source DB:  PubMed          Journal:  Acta Neurochir Suppl (Wien)


  4 in total

1.  A prospective study of cavernous sinus surgery for meningiomas and resultant common ophthalmic complications (an American Ophthalmological Society thesis).

Authors:  Steven Newman
Journal:  Trans Am Ophthalmol Soc       Date:  2007

2.  High sensitivity of the in vivo detection of somatostatin receptors by 111indium (DTPA-octreotide)-scintigraphy in meningioma patients.

Authors:  G Hildebrandt; K Scheidhauer; C Luyken; H Schicha; N Klug; P Dahms; B Krisch
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

Review 3.  Review of skull base surgery approaches: with special reference to pediatric patients.

Authors:  J D Kennedy; S J Haines
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 4.  Midline Skull Base Meningiomas: Transcranial and Endonasal Perspectives.

Authors:  Ciro Mastantuoni; Luigi Maria Cavallo; Felice Esposito; Elena d'Avella; Oreste de Divitiis; Teresa Somma; Andrea Bocchino; Gianluca Lorenzo Fabozzi; Paolo Cappabianca; Domenico Solari
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.